Not exact matches
Although the
gene / cell
therapy strategy was highly successful in laboratory mice, the authors stressed that additional
research and testing are needed
before the
therapy could be tested in humans.
Formerly a
research leader at CHOP, High pursued groundbreaking preclinical investigations in hemophilia B
gene therapy and provided scientific expertise to previous
gene therapy trials in hemophilia and other genetic disorders at CHOP
before moving to Spark Therapeutics, which was spun off from CHOP in 2013.
Before joining RPCI, Dr. Koya was previously an assistant professor in the Department of Surgery, Division of Surgical Oncology, UCLA, with
research focus in cancer
gene therapy and immunology.